- Home
- DAWN vs SASR Comparison
DAWN vs SASR Comparison
Compare DAWN & SASR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- SASR
- Stock Information
- Founded
- DAWN 2018
- SASR 1868
- Country
- DAWN United States
- SASR United States
- Employees
- DAWN N/A
- SASR N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- SASR Major Banks
- Sector
- DAWN Health Care
- SASR Finance
- Exchange
- DAWN Nasdaq
- SASR Nasdaq
- Market Cap
- DAWN 1.3B
- SASR N/A
- IPO Year
- DAWN 2021
- SASR 1996
- Fundamental
- Price
- DAWN $12.15
- SASR $34.28
- Analyst Decision
- DAWN Strong Buy
- SASR Hold
- Analyst Count
- DAWN 7
- SASR 4
- Target Price
- DAWN $36.33
- SASR $29.33
- AVG Volume (30 Days)
- DAWN 1.1M
- SASR 254.4K
- Earning Date
- DAWN 02-24-2025
- SASR 01-28-2025
- Dividend Yield
- DAWN N/A
- SASR 4.00%
- EPS Growth
- DAWN N/A
- SASR N/A
- EPS
- DAWN N/A
- SASR 0.44
- Revenue
- DAWN $101,953,000.00
- SASR $392,249,000.00
- Revenue This Year
- DAWN N/A
- SASR N/A
- Revenue Next Year
- DAWN $34.82
- SASR $17.83
- P/E Ratio
- DAWN N/A
- SASR $75.18
- Revenue Growth
- DAWN N/A
- SASR N/A
- 52 Week Low
- DAWN $11.13
- SASR $19.52
- 52 Week High
- DAWN $18.07
- SASR $39.55
- Technical
- Relative Strength Index (RSI)
- DAWN 44.59
- SASR 44.92
- Support Level
- DAWN $11.93
- SASR $33.22
- Resistance Level
- DAWN $13.53
- SASR $34.41
- Average True Range (ATR)
- DAWN 0.56
- SASR 1.14
- MACD
- DAWN 0.03
- SASR 0.13
- Stochastic Oscillator
- DAWN 35.21
- SASR 36.34
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.